{Reference Type}: Journal Article
{Title}: Pharmacotherapy for osteoarthritis-related pain: current and emerging therapies.
{Author}: Zhang M;Wang Z;Ding C;
{Journal}: Expert Opin Pharmacother
{Volume}: 0
{Issue}: 0
{Year}: 2024 Jun 27
{Factor}: 4.103
{DOI}: 10.1080/14656566.2024.2374464
{Abstract}: <B>UNASSIGNED: </B>Osteoarthritis (OA) related pain has affected millions of people worldwide. However, the current pharmacological options for managing OA-related pain have not achieved a satisfactory effect.<BR><B>UNASSIGNED: </B>This narrative review provides an overview of the current and emerging drugs for OA-related pain. It covers the drugs' mechanism of action, safety, efficacy, and limitations. The National Library of Medicine (PubMed) database was primarily searched from 2000 to 2024.<BR><B>UNASSIGNED: </B>Current treatment options are limited and suboptimal for OA pain management. Topical nonsteroidal anti-inflammatory drugs (NSAIDs) are the recognized and first-line treatment in the management of OA-related pain, and other drugs are inconsistent recommendations by guidelines. Emerging treatment options are promising for OA-related pain, including nerve growth factor (NGF) inhibitors, ion channel inhibitors, and calcitonin gene-related peptide (CGRP) antagonists. Besides, drugs repurposing from antidepressants and antiepileptic analgesics are shedding light on the management of OA-related pain. The management of OA-related pain is challenging as pain is heterogeneous and subjective. A more comprehensive strategy combined with non-pharmacological therapy needs to be considered, and tailored management options to individualized patients.